ROSGQ (Rosetta Genomics) YoY EPS Growth: 66.25% (As of Jun. 2017)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Rosetta Genomics YoY EPS Growth?

Rosetta Genomics ROSGQ YoY EPS Growth is 66.25% as of Jun. 2017.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Rosetta Genomics's YoY EPS Growth for the quarter that ended in Jun. 2017 was 66.25%.

Rosetta Genomics's Earnings per Share (Diluted) for the three months ended in Jun. 2017 was $-0.81.

Rosetta Genomics YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Rosetta Genomics's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rosetta Genomics YoY EPS Growth Chart

Rosetta Genomics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 86.49 42.98 3.73 10.85 32.17

Rosetta Genomics Quarterly Data
Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Mar16 Jun16 Sep16 Dec16 Jun17
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 98.33 84.52 95.48 99.30 66.25

Rosetta Genomics YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Rosetta Genomics's YoY EPS Growth for the fiscal year that ended in Dec. 2016 is calculated as:

YoY EPS Growth (A: Dec. 2016 )
=(Earnings per Share (Diluted) (A: Dec. 2016 )-Earnings per Share (Diluted) (A: Dec. 2015 ))/ | Earnings per Share (Diluted) (A: Dec. 2015 ) |
=(-9.36--13.8)/ | -13.8 |
=32.17 %

Rosetta Genomics's YoY EPS Growth for the quarter that ended in Jun. 2017 is calculated as:

YoY EPS Growth (Q: Jun. 2017 )
=(Earnings per Share (Diluted) (Q: Jun. 2017 )-Earnings per Share (Diluted) (Q: Mar. 2016 )) / | Earnings per Share (Diluted) (Q: Mar. 2016 )) |
=(-0.81--2.4)/ | -2.4 |
=66.25 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 66.25% mean?
Rosetta Genomics (ROSGQ) has a YoY EPS Growth of 66.25% as of Jun. 2017. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Rosetta Genomics and its competitors.
Is Rosetta Genomics' YoY EPS Growth too high?
Rosetta Genomics' current YoY EPS Growth is 66.25%.
How does Rosetta Genomics' YoY EPS Growth compare to TEAR and IDTA?
Rosetta Genomics' YoY EPS Growth of 66.25% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Medical Diagnostics & Research company?
A good YoY EPS Growth depends on the Medical Diagnostics & Research industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Rosetta Genomics and its competitors. Rosetta Genomics's current YoY EPS Growth is 66.25%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rosetta Genomics stock overvalued right now?
Rosetta Genomics (ROSGQ) has a current YoY EPS Growth of 66.25%. The current YoY EPS Growth is 66.25%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Rosetta Genomics (ROSGQ), the current YoY EPS Growth is 66.25% as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rosetta Genomics Business Description

Address 10 Plaut Street, Science Park, Rehovot, ISR, 76706
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.